FLEURUS MEDICAL
Board
2 directors, no change since 2019Manager (not named in the articles)
appointed by deed of 08-11-2007
term without a fixed end
listed in the 2025 annual accounts, filed on 20-10-2026
Manager
appointed by deed of 04-06-2019
term without a fixed end
listed in the 2025 annual accounts, filed on 20-10-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Each manager alonedeed of 08-11-2007
Mandates through the years
2 names, the dashed line is todayManager (not named in the articles)
Manager
Board
Mandates as a list
-
- Manager (not named in the articles), appointed by deed of 08-11-2007, still in office
-
- Manager, appointed by deed of 04-06-2019, still in office
With Starter you also see 1 former office holder in the mandate history.
See the plans →
Control
Shareholder
1,775 voting rights
50%
This company
FLEURUS MEDICAL
Equity -€253,976
Loss €427,073 in 2025
Capital
- Contribution
- €600,000
- Source
- 2025 annual accounts
Owners through the years
as the annual accounts name themOwners as a list
Source: shareholder structure in its own accounts
Articles of association
deed of 30-12-2024 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- Moitié cédant moitié acquéreurs proportionnellement nombre actions, écrit par pli recommandé
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Second Tuesday of March at 18:00
Shareholders
3 ownersOwners 3
- individual shareholderSourceown accounts 201750%
- individual shareholderSourceown accounts 201725%
- individual shareholderSourceown accounts 201725%
Capital transactions
Shareholders according to the deeds
After the capital increase
deed of 30-12-2024 ↗
- €291,997.80 in kind
- €100,000 in kind
- €120,000 in kind
Capital over time
- 30-12-2024 Capital increase of €511,997.80 · to €600 · 20,654 new shares at €24.79 per share · in kind
- 30-12-2024 Converted to unavailable equity